Bioptik Technology Incorporation (TPEX:4161)

Market Cap	1.50B -16.0%
Revenue (ttm)	837.19M -3.3%
Net Income	71.19M -23.9%
EPS	1.21 -23.9%
Shares Out	59.81M
PE Ratio	20.70
Forward PE	n/a
Dividend	0.70 (2.79%)
Ex-Dividend Date	n/a

Volume	22,616
Average Volume	48,822
Open	25.40
Previous Close	25.40
Day's Range	25.05 - 25.65
52-Week Range	23.70 - 30.97
Beta	0.32
RSI	46.07
Earnings Date	Apr 2, 2026

About TPEX:4161

Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. It offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch Glucose Monitoring System for Dogs and Cats. The company also provides dietary supplements, such as capsules, gel capsules, tablets, solutions, powder sachet, jelly, and gummy; cosmetic products, including sunscreen, ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4161

Financial Performance

In 2025, TPEX:4161's revenue was 837.19 million, a decrease of -3.25% compared to the previous year's 865.34 million. Earnings were 71.19 million, a decrease of -23.92%.